Study on the role of tissue-specific and non-specific autoantibodies, matrix metalloproteinase-3 and neuron-specific enolase enzymes in the exacerbation of autoimmune thyroiditis
DOI:
https://doi.org/10.14739/2310-1210.2024.2.296844Keywords:
autoimmune thyroiditis, neuron-specific enolase, matrix metalloproteinase 3, autoantibodies, Ab-dsDNAAbstract
The aim of the study was to examine the involvement of tissue-specific and non-specific autoantibodies, matrix metalloproteinase-3 and neuron-specific enolase (NSE) enzymes in the development and exacerbation of autoimmune thyroiditis.
Materials and methods. The study enrolled 170 patients with autoimmune thyroiditis (64 males and 106 females aged 18 to 64 years) to comprehensively examine their humoral immune response indicators (IgA, M, G), organ-specific (Ab-TG, Ab-TPO) and organ-non-specific antibodies (Ab-DNA), metalloproteinase-3 and NSE activity. The control group consisted of 65 individuals without thyroid pathologies or other autoimmune diseases, aged 20 to 65 years (26 males and 39 females).
Results. The study has demonstrated changes in the levels of organ-specific and organ-nonspecific antibodies and statistically significantly increased metalloproteinase-3 activity in patients with autoimmune thyroiditis. Positive correlations have been found between elevated levels of IgG, Ab-TG, Ab-TPO, Ab-dsDNA and NSE activity. Negative correlations have been observed between NSE activity and IgA concentrations.
Conclusions. Elevated titers of anti-DNA autoantibodies may indicate an aggravation of the autoimmune process due to cellular structure damage, resulting in gland dysfunction. The findings also suggest that metalloproteinase-3, a marker predicting thyroid tissue damage, may negatively impact the immune response induction, ultimately affecting the activity of neuron-specific enolase. The data have shown that studying biochemical indicators such as antinuclear antibodies (ANA), anti-DNA antibodies, metalloproteinase-3 and neurodegenerative indicators could provide informative markers to determine the nature of the disease development and worsening.
References
Ralli M, Angeletti D, Fiore M, D'Aguanno V, Lambiase A, Artico M, de Vincentiis M, Greco A. Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun Rev. 2020;19(10):102649. doi: https://doi.org/10.1016/j.autrev.2020.102649
Ragusa F, Fallahi P, Elia G, Gonnella D, Paparo SR, Giusti C, et al. Hashimotos' thyroiditis: Epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101367. doi: https://doi.org/10.1016/j.beem.2019.101367
Rahimova RR. Relationship between CTLA4, TNF-α and PTPN22 gene polymorphism and the serum levels of antithyroglobulin and antiperoxidase antibodies in autoimmune thyroiditis. AIMS Medical Science. 2023;10(1):14-23. doi: https://doi.org/10.3934/medsci.2023002
Horiya M, Anno T, Kawasaki F, Iwamoto Y, Irie S, Monobe Y, et al. Basedow's disease with associated features of Hashimoto's thyroiditis based on histopathological findings. BMC Endocr Disord. 2020;20(1):120. doi: https://doi.org/10.1186/s12902-020-00602-8
Yoneda M. [Hashimoto's encephalopathy and autoantibodies]. Brain Nerve. 2013;65(4):365-76. Japanese
Klose CSN, Veiga-Fernandes H. Neuroimmune interactions in peripheral tissues. Eur J Immunol. 2021;51(7):1602-14. doi: https://doi.org/10.1002/eji.202048812
Valencia-Sanchez C, Pittock SJ, Mead-Harvey C, Dubey D, Flanagan EP, Lopez-Chiriboga S, et al. Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Commun. 2021;3(2):fcaa233. doi: https://doi.org/10.1093/braincomms/fcaa233
Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. Int J Mol Sci. 2020;21(24):9739. doi: https://doi.org/10.3390/ijms21249739
Rahimova RR. (2022). Study of matrix metalloproteinase activity in patients with autoimmune thyroiditis. Ukr. Biochem. J. 2022;94(2):51-6. doi: https://doi.org/10.15407/ubj94.02.051
Salomão R, Assis V, de Sousa Neto IV, Petriz B, Babault N, Durigan JLQ, et al. Involvement of Matrix Metalloproteinases in COVID-19: Molecular Targets, Mechanisms, and Insights for Therapeutic Interventions. Biology (Basel). 2023;12(6):843. doi: https://doi.org/10.3390/biology12060843
Lech AM, Wiera G, Mozrzymas JW. Matrix metalloproteinase-3 in brain physiology and neurodegeneration. Adv Clin Exp Med. 2019;28(12):1717-22. doi: https://doi.org/10.17219/acem/110319
Wan J, Zhang G, Li X, Qiu X, Ouyang J, Dai J, et al. Matrix Metalloproteinase 3: A Promoting and Destabilizing Factor in the Pathogenesis of Disease and Cell Differentiation. Front Physiol. 2021;12:663978. doi: https://doi.org/10.3389/fphys.2021.663978
Weetman AP. An update on the pathogenesis of Hashimoto's thyroiditis. J Endocrinol Invest. 2021;44(5):883-90. doi: https://doi.org/10.1007/s40618-020-01477-1
Pérez AR, Maya-Monteiro CM, Carvalho VF. Editorial: Neuroendocrine-Immunological Interactions in Health and Disease. Front Endocrinol (Lausanne). 2021;12:718893. doi: https://doi.org/10.3389/fendo.2021.718893
Gothié JD, Vancamp P, Demeneix B, Remaud S. Thyroid hormone regulation of neural stem cell fate: From development to ageing. Acta Physiol (Oxf). 2020;228(1):e13316. doi: https://doi.org/10.1111/apha.13316
Głombik K, Detka J, Budziszewska B. Hormonal Regulation of Oxidative Phosphorylation in the Brain in Health and Disease. Cells. 2021;10(11):2937. doi: https://doi.org/10.3390/cells10112937
Ganti L, Serrano E, Toklu HZ. Can Neuron Specific Enolase Be a Diagnostic Biomarker for Neuronal Injury in COVID-19? Cureus. 2020;12(10):e11033. doi: https://doi.org/10.7759/cureus.11033
Camats N, Baz-Redón N, Fernández-Cancio M, Clemente M, Campos-Martorell A, Jaimes N, et al. Phenotypic Variability of Patients With PAX8 Variants Presenting With Congenital Hypothyroidism and Eutopic Thyroid. J Clin Endocrinol Metab. 2021;106(1):e152-70. doi: https://doi.org/10.1210/clinem/dgaa711
Lu Y, Qin J, Xiang Y, Sun R, Feng Y, Zhang H, et al. Experimental evidence for alpha enolase as one potential autoantigen in the pathogenesis of both autoimmune thyroiditis and its related encephalopathy. Int Immunopharmacol. 2020;85:106563. doi: https://doi.org/10.1016/j.intimp.2020.106563
Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, et al. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2020;2(12):1413-1426. doi: https://doi.org/10.1038/s42255-020-00313-3
Pisetsky DS, Garza Reyna A, Belina ME, Spencer DM. The Interaction of Anti-DNA Antibodies with DNA: Evidence for Unconventional Binding Mechanisms. Int J Mol Sci. 2022;23(9):5227. doi: https://doi.org/10.3390/ijms23095227
Ząbczyńska M, Link-Lenczowski P, Novokmet M, Martin T, Turek-Jabrocka R, Trofimiuk-Müldner M, et al. Altered N-glycan profile of IgG-depleted serum proteins in Hashimoto's thyroiditis. Biochim Biophys Acta Gen Subj. 2020;1864(3):129464. doi: https://doi.org/10.1016/j.bbagen.2019.129464
Granito A, Muratori L, Tovoli F, Muratori P. Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis. Nat Rev Rheumatol. 2021;17(4):244. doi: https://doi.org/10.1038/s41584-021-00573-7
Ivković I, Limani Z, Jakovčević A, Huić D, Prgomet D. Role of Matrix Metalloproteinases and Their Inhibitors in Locally Invasive Papillary Thyroid Cancer. Biomedicines. 2022;10(12):3178. doi: https://doi.org/10.3390/biomedicines10123178
He L, Kang Q, Chan KI, Zhang Y, Zhong Z, Tan W. The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer. Front Immunol. 2023;13:1093990. doi: https://doi.org/10.3389/fimmu.2022.1093990
Zipfel P, Rochais C, Baranger K, Rivera S, Dallemagne P. Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and Challenges. J Med Chem. 2020;63(19):10705-25. doi: https://doi.org/10.1021/acs.jmedchem.0c00352
Xu CM, Luo YL, Li S, Li ZX, Jiang L, et al. Multifunctional neuron-specific enolase: its role in lung diseases. Biosci Rep. 2019;39(11):BSR20192732. doi: https://doi.org/10.1042/BSR20192732
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
